All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Evaluating Antimalarial Proteasome Inhibitors for Efficacy in Babesia Blood Stage Cultures

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F24%3A00601793" target="_blank" >RIV/60077344:_____/24:00601793 - isvavai.cz</a>

  • Alternative codes found

    RIV/61388963:_____/24:00601793 RIV/60076658:12310/24:43908696

  • Result on the web

    <a href="https://doi.org/10.1021/acsomega.4c04564" target="_blank" >https://doi.org/10.1021/acsomega.4c04564</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1021/acsomega.4c04564" target="_blank" >10.1021/acsomega.4c04564</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Evaluating Antimalarial Proteasome Inhibitors for Efficacy in Babesia Blood Stage Cultures

  • Original language description

    Tick-transmitted Babesia are a major global veterinary threat and an emerging risk to humans. Unlike their Plasmodium relatives, these erythrocyte-infecting Apicomplexa have been largely overlooked and lack specific treatment. Selective targeting of the Babesia proteasome holds promise for drug development. In this study, we screened a library of peptide epoxyketone inhibitors derived from the marine natural product carmaphycin B for their activity against Babesia. Several of these compounds showed activity against both the asexual and sexual blood stages of Plasmodium falciparum. These compounds inactivate beta 5 proteasome subunit activity in the lysates of Babesia divergens and Babesia microti in the low nanomolar range. Several compounds were tested with the purified B. divergens proteasome and showed IC50 values comparable to carfilzomib, an approved anticancer proteasome inhibitor. They also inhibited B. divergens growth in bovine erythrocyte cultures with solid EC50 values, but importantly, they appeared less toxic to human cells than carfilzomib. These compounds therefore offer a wider therapeutic window and provide new insights into the development of small proteasome inhibitors as selective drugs for babesiosis.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    10606 - Microbiology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2024

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    ACS Omega

  • ISSN

    2470-1343

  • e-ISSN

    2470-1343

  • Volume of the periodical

    9

  • Issue of the periodical within the volume

    45

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    11

  • Pages from-to

    44989-44999

  • UT code for WoS article

    001344916100001

  • EID of the result in the Scopus database

    2-s2.0-85207418461